| Code | CSB-RA007670MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to HuL-001, targeting ENO1 (Enolase 1, also known as alpha-enolase). ENO1 is a multifunctional glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate in the glycolytic pathway. Beyond its metabolic role, ENO1 functions as a plasminogen receptor on cell surfaces, promoting cell migration and invasion. This protein is significantly overexpressed in various malignancies, including lung, breast, pancreatic, and hepatocellular carcinomas, where it contributes to tumor progression, metastasis, and serves as a potential diagnostic and prognostic biomarker. ENO1 is also expressed on the surface of pathogenic microorganisms and has been implicated in autoimmune conditions.
HuL-001 is a reference antibody utilized in cancer research and studies investigating ENO1's role in cellular metabolism and disease pathogenesis. This biosimilar provides researchers with a reliable tool for exploring ENO1-mediated mechanisms in oncology, metabolic disorders, and infectious disease models, facilitating investigations into therapeutic targeting strategies.
There are currently no reviews for this product.